Alteogen Biologics to Introduce Papilocare HPV Medical Device in South Korea
Alteogen Biologics, a subsidiary of Alteogen, secured the domestic commercial rights for Papilocare, a specialized vaginal gel designed to manage human papillomavirus infections and associated cervical lesions, through a licensing agreement announced on September 16 with Spain’s Procare Health. The product aims to accelerate re-epithelialization of the cervical and vaginal mucosa, providing a structured care option where few targeted non-surgical interventions exist.
- Alteogen Biologics partnered with Procare Health on September 16 to distribute the vaginal gel Papilocare in South Korea.
- Randomized controlled trials, specifically PALOMA 1 and PALOMA 2, demonstrated an 85.4% clearance rate for high-risk HPV at six months in the treatment group compared to 43.4% in the control group.
- The treatment addresses clinical gaps for persistent high-risk HPV and low-grade cervical lesions, expanding Alteogen Biologics’ women’s health portfolio beyond its existing distribution of LG Chem’s anti-adhesion agent Protescal.
Clinical Rationale and Managing Persistent HPV Infections
Human papillomavirus represents one of the most common viral infections globally. While the immune system clears most cases spontaneously, persistent high-risk HPV infections can drive cervical intraepithelial neoplasia and potentially progress toward cervical cancer. Standard clinical protocols for patients testing positive for high-risk strains or presenting with low-grade cervical lesions historically rely on active surveillance through regular cytologic screening and colposcopy rather than direct pharmacological elimination.
To evaluate potential interventions for this clinical gap, researchers designed the European randomized controlled trials PALOMA 1 and PALOMA 2. According to trial data reported by Alteogen Biologics, a pooled analysis of PALOMA 1 and PALOMA 2 showed that the 6-month clearance rate of high-risk HPV reached 85.4% among patients using the vaginal gel, contrasting with 43.4% in the control cohort. Furthermore, data from PALOMA 2 indicated that the normalization rate for high-risk HPV-associated low-grade cervical lesions reached 84.6% in the treatment group, compared to 46.4% in the control group.
Commercial Expansion and Portfolio Integration in Women’s Health
Alteogen Biologics builds upon an established operational foundation in domestic obstetrics and gynecology, anchored by its distribution, sales, and marketing responsibilities for LG Chem’s anti-adhesion agent Protescal. Integrating the new vaginal gel broadens the company’s scope into viral clearance and mucosal recovery.
An official representative of Alteogen Biologics stated that because persistent high-risk HPV infections and subsequent cervical lesions leave patients with restricted management options, introducing an evidence-based medical device offers a tangible therapeutic alternative. The company intends to leverage its existing provider network to make the product accessible to specialists.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*